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  E
thical issues are a growing 
concern for companies, in the 
wake of a series of corporate 
governance scandals and the 
accompanying sharp decline in societal 
and investor trust in ﬁ  rms. Some 
companies have responded to these 
concerns by creating internal ethics 
programs. In the aerospace sector, 
for example, companies have focused 
these efforts on ensuring compliance 
with government regulations, while in 
the energy sector, ethics initiatives have 
concentrated on environmental issues 
and corporate and social responsibility 
[1]. 
    Companies in pharmaceutical, 
biotech, and bioagricultural industries 
must not only comply with a wide 
array of government regulations and 
balance the proﬁ  t motive with social 
responsibility, but also must deal 
with the complex array of ethical 
issues raised by doing business in the 
biosciences. These complex issues 
include the production and sale of 
genetically modiﬁ  ed foods; gene 
therapy experiments and embryonic 
stem cell research to produce 
new therapies; animal testing for 
pharmaceuticals; drug pricing at 
home and in developing countries; the 
potential misuse of personal genetic 
information; how to appropriately 
commercialize and proﬁ  t from genetic 
and biological samples; and the 
creation of transgenic animals for drug 
production.
    Although a theoretical debate rages 
about whether bioethicists should 
consult to industry [2,3], no one has 
systematically examined from the 
standpoint of bioscience companies 
themselves how they address these 
ethical issues and why they do so. 
In understanding the complex 
relationship between bioethics and 
industry, there is a need to obtain 
insight from the people closest to 
the phenomenon. Some researchers 
would like to discount the views of 
corporate managers, but to do so would 
inappropriately ignore a very legitimate 
viewpoint, and a good starting place to 
begin to understand the issues faced, 
and approaches taken, by companies. 
To address this gap, our research team 
sought to uncover how bioscience 
companies, from global corporations 
to small start-ups, address ethical 
challenges speciﬁ  c to bioscience ﬁ  rms. 
    Using the case study method (see 
Box 1), we performed more than 
100 in-depth, face-to-face interviews 
with top managers and executives 
at 13 bioscience companies to learn 
about bioindustry ethics from their 
perspective (see Table 1 for a list and 
description of the 13 companies). 
Of the 13 companies, the majority 
can be classiﬁ  ed as biotechnology 
companies, engaged in developing 
medical products, tools, and 
bioagricultural or industrial products. 
We also chose to include some 
companies for comparison that are 
part of the biotech value chain: a few 
pharmaceutical companies that often 
partner with biotechnology ﬁ  rms, and 
a contract research organization that 
is a supplier to biotech ﬁ  rms; thus, we 
use the term bioscience rather than 
biotech. We invited 19 companies to 
take part in the project, and 13 agreed 
(four pharmaceutical, one biotech, 
and one bioagricultural company 
declined). 
    The companies were not approached 
because they were representative of the 
bioscience industry, but rather because 
we knew they had implemented 
interesting and varied mechanisms 
to address ethical decision making 
from which we felt the rest of the 
industry could learn. In our selection, 
we were also looking for variety in 
company size, type, and location. The 
individual company case studies have 
been published as a book,   BioIndustry 
Ethics   [4], and each case provides a 
detailed examination of the company, 
the ethical issues it faces, and the 
mechanisms the company is using to 
address these issues.
    What was not covered in the book 
(and is reported in this article) are the 
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ﬁ  ndings from a cross-case comparative 
analysis of the 13 case studies. The data 
were analyzed under four themes. The 
ﬁ  rst theme, and focus of this article, 
examined what mechanisms are being 
used by these companies to address 
ethical issues. This theme produced 
a list of mechanisms that can help to 
address bioindustry ethics; these are 
highlighted in Box 2 and described 
below. The second theme of our 
analysis was an attempt to see how the 
companies evaluated the effectiveness 
of their ethics mechanisms. As will 
be discussed, this theme, although 
important, has only been incorporated 
by a few companies in our study, and 
only on a preliminary basis, illustrating 
that this area requires further research 
and development. 
    Although not discussed at length 
in this article, the third theme was 
to understand the reasons why these 
companies have decided to address 
ethical issues, and the fourth theme 
was to learn what ethical issues these 
companies are facing. The results 
from theme three produced a list of 
six reasons why these companies are 
addressing bioindustry ethics (Box 
3), and the ethical issues facing each 
ﬁ  rm from theme four are described in 
Table 2. 
    How Are Bioscience Companies 
Addressing Bioethics? 
    Our study revealed a variety of 
mechanisms that are presently 
being used by bioscience companies 
to address ethical issues. These 
mechanisms offer insight and provide 
ideas on how other bioscience 
companies could implement 
mechanisms in their ﬁ  rms to address 
their own ethical issues. The speciﬁ  c 
mechanisms fall into ﬁ  ve mutually 
reinforcing approaches (Box 2). All of 
our ﬁ  ndings represent a snapshot of 
what these companies were doing to 
address bioindustry ethics at the time of 
our interviews. 
    Approach One: Ethical Leadership
      Founder/CEO/management ethical 
leadership.   Ethical sensitivity and 
behaviour often spring from a 
company’s founders or current 
leadership. All 13 companies 
mentioned ethical leadership as a 
key component of their approach to 
ethics. For some, a CEO or an ethical 
leader within the company was the 
driving force behind their approach to 
ethics. At Millennium Pharmaceuticals, 
the CEO/Founder’s commitment to 
ethics was the driving force behind the 
company’s ethical culture. Their VP of 
Ethics and Corporate Responsibility 
explained: “In the business ethics arena 
it is particularly important…to have 
an identiﬁ  able leader with charisma 
and a deep sense of commitment 
to the institution and someone who 
models ethical behaviour for his or her 
employees.” 
      An ethics department.   As companies 
grow, we found that they tend to 
become more systematic in the way 
they address ethics. While some of the 
small- and medium-sized companies 
employed individuals, including key 
business leaders who included ethics as 
part of their job responsibilities, several 
of the larger companies we studied 
developed separate departments 
whose sole focus is to address ethical 
issues. Merck and Millennium both 
have an internal Ethics Ofﬁ  ce, where 
individuals with an ethical issue can 
go for a conﬁ  dential consultation. 
Novo Nordisk has several divisions 
within the company that drive and 
monitor the company’s Triple 
Bottom Line (social, environmental, 
ﬁ  nancial) performance. They also 
have a Bioethics Director focused 
on addressing the company’s 
environmental, human, and animal-
related ethical issues. 
    Approach Two: External Expertise
      External ethics consultant.   Several 
of the companies used external 
consultants at various stages in 
their development to provide ethics 
education or expertise that was missing 
internally. For Sciona, which was 
still in its start-up phase, an external 
ethics consultant was its primary ethics 
mechanism. Sciona’s consultant helped 
the company navigate the ethical 
issues associated with its business of 
providing genetic-based health and 
diet information. The consultant 
reviewed marketing material to make 
sure it was ethically appropriate for the 
audience and encouraged the company 
to re-think its direct-to-consumer sales 
approach and to engage in a dialogue 
with the United Kingdom Human 
Genetics Commission.
      Ethics advisory boards.   Ethics 
Advisory Boards (EABs) were used 
as the primary mechanism by two 
of the medium-sized companies, 
PharmaSNPs (this company was 
acquired and no longer exists, and as 
a result, the company name has been 
anonymized) and Affymetrix, as a 
    Qualitative case study methods were 
used for this research.
   Data  Collection
      Data was collected over a two-year 
period, using a study design approved by 
the University of Toronto research ethics 
board. Our research team performed 
in-depth, open-ended interviews with 
managers and executives from 13 
bioscience companies (more than 100 
interviews in total). Media articles, press 
releases, and company documents were 
also analyzed to verify the data resulting 
from the interviews.
   Data  Sources
   Data was drawn from (1) interview notes, 
(2) observations from company visits, and 
(3) written documents (produced by the 
company and by other sources). 
   Data  Analysis
      Case Studies. The three sources of 
data were analyzed for each company 
independently to produce 13 qualitative 
case studies describing ethical decision 
making in each company. These case 
studies were veriﬁ  ed for accuracy and 
approved for publication by each ﬁ  rm.
    Cross-Case Comparison. To perform 
the comparison, the case studies and 
interview notes were coded on four 
themes: (1) What mechanisms are 
bioscience companies using to address 
their ethical issues? (2) How effective 
are their mechanisms? (3) Why have 
these bioscience companies decided 
to implement ethics mechanisms? (4) 
What ethical issues are these bioscience 
companies facing and addressing with 
the previously mentioned mechanisms?
    In qualitative research, this is known 
as axial coding. This coding process was 
performed ﬁ  rst by one of our researchers 
and then veriﬁ  ed for validity by other 
team members. Any discrepancies in 
results were discussed until consensus 
was reached. 
    The results from Themes 1 and 2 are 
discussed in the text of this article, and 
Themes 3 and 4 are addressed in Box 3 
and Table 2, respectively. 
  Box 1. Research Methodology
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mechanism to provide independent 
guidance and advice on ethical issues 
the companies faced. The EABs 
were composed of outside members 
representing the ﬁ  elds of medicine, 
law, religion, and ethics—and at one 
of the companies, lay members of 
the general public. The members 
would meet on a regular basis and 
would discuss, debate, and provide 
actionable guidance on speciﬁ  c issues. 
An Affymetrix EAB member explained 
one of the roles of the EAB: “We 
hold space, a focus and a safe place 
for [the company] to have non-core 
business discussions. To ask questions 
like: ‘Is there anything wrong with this 
deal?’ or ‘How far should we go to be 
ethical?’ We help them clarify why a 
certain activity is acceptable and why 
other choices are not.”
    Approach Three: Internal Ethics 
Mechanisms 
      Hiring practices focused on ethics.   
Some companies in our study are now 
putting weight on candidates’ values, 
in addition to their past performance 
and technical expertise, when making 
hiring decisions. Six of the companies 
in this study include interview questions 
during the hiring process that aim to 
assess how the potential employee’s 
values align with the ethical values of 
the company. For example, employees 
from both Millennium and Maxim 
explained that technical skills and 
experience are now combined with the 
candidate’s behavioural and ethical ﬁ  t 
when assessing the candidate’s merits.
      Employee performance evaluations.   
A key driver of employee behaviour 
in any organization is the types of 
behaviours that are rewarded and 
promoted by upper management. One 








Location of Headquarters  Company Description
Interleukin Genetics 8–22 1986 Public Waltham, Massachusetts, United 
States of America
A nutrigenomics company focused on 
performing clinical trials that examine the impact 
of genes on nutrition.
Sciona 10 2001 Private United Kingdom (recently 
relocated to Boulder, Colorado, 
United States of America) 
A small, personalized health-care company 
focused on nutrigenomics (genetic testing based 
on nutrition).
TGN Biotech 20 2000 Private Quebec City, Quebec, Canada A start-up biotech company focused on 
transgenic technology to produce recombinant 
therapeutic proteins in the seminal ﬂ  uid of 
transgenic hogs.
Pipeline Biotech 20 1999 Private Denmark A small contract research organization 
specializing in animal testing.
PharmaSNPs* N/A N/A N/A N/A A genomics ﬁ  rm that was focused on identifying 
genetic linkages with major diseases. The 
company has been acquired and now operates 
as a subsidiary of a larger ﬁ  rm. 
Maxim Pharmaceuticals 150 1993 Public San Diego, California, United 
States of America
A company developing a range of therapeutics 
based on naturally occurring histamines.
Diversa 280 1994 Public San Diego, California, United 
States of America
A company developing products from genetic 
and biological resources found in biodiversity.
Affymetrix 900 1991 Public Santa Clara, California, United 
States of America
A pioneering company in the development of 
gene chips.
Genzyme 6,500 1981 Public Cambridge, Massachusetts, United 
States of America
The world’s fourth largest biotech company and 
a leader in the development of ultra-orphan 
drugs for rare genetic disorders.
Millennium Pharmaceuticals 13,700 1993 Public Cambridge, Massachusetts, 
United States of America
A biopharmaceutical company with a broad drug 
development platform.
Monsanto 13,700 1901 Public St. Louis, Missouri, United States 
of America
A leading multinational agricultural 
biotechnology company that produces 
genetically modiﬁ  ed seeds, herbicides, and a 
bovine growth hormone.




Public Copenhagen, Denmark A large Danish biopharmaceutical company 
focused on diabetes care. Other product focuses 
include homeostasis management, human 
growth therapy, and hormone replacement 
therapy.
Merck 60,000 1887 Public Whitehouse Station, Massachusetts, 
United States of America
One of the world’s largest research-driven 
pharmaceutical companies, with products for the 
treatment of cancer, HIV/AIDS, baldness, asthma, 
seasonal allergies, osteoarthritis, heart disease, 
stroke, and more.
  Asterisk indicates pseudonym for company. Details on size and location not revealed to protect the ﬁ  rm’s identity.
    The information in this table was correct at the time of the study. In our analysis, the companies are divided into small, medium, and large based on employee numbers. The smaller companies at the time of the interviews 
had fewer than 30 employees, the medium between 30 and 999, and the larger over 1,000.
  DOI:  10.1371/journal.pmed.0030129.t001 
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medium-sized and three large-sized 
companies that were interviewed have 
incorporated ethics into employee 
performance reviews. For example, 
a Merck interviewee explained that 
the intention when designing a 
performance system is to not create 
incentives that encourage employees 
to bend the rules. The employee said: 
“We try not to put people in situations 
where they have to ‘make a number’ 
so that they won’t be tempted to give a 
$10,000 research grant to a doctor just 
to make a sale and meet that number.”
      Ethics education and forums for 
ethics discussion.   The majority of the 
medium- and large-sized companies 
we interviewed have developed 
formal ethics education sessions on 
topics such as research ethics and 
informed consent. Several of these 
ﬁ  rms have also introduced less formal 
forums for ethics discussion, where 
employees can voice concerns and 
have questions answered. At Monsanto, 
these are called “town hall meetings.” 
Millennium used popular ﬁ  lm 
screenings—e.g.,   Gattaca   and   Inherit the 
Wind  —facilitated by an outside ethics 
expert to draw out issues for ethics 
debates among employees. Millennium, 
Genzyme, and Merck have also 
implemented an Ethics Helpline that 
employees can call anonymously to get 
guidance about ethical issues.
      Ethical reinforcement techniques.   
All of the companies we interviewed 
use techniques to reinforce ethics 
within the company, although these 
techniques tend to be more formally 
organized in the larger ﬁ  rms. Some try 
to remind employees of the importance 
of ethics by deﬁ  ning core values as 
part of the company’s culture (such as 
Genzyme’s “Putting the Patient First” 
approach), and some provide oral 
and visual reinforcements (by printing 
them on placards around the company 
buildings or on employees’ mouse pads, 
as at Millennium). Ethical guidelines 
in areas such as clinical trials and sales 
and marketing of pharmaceuticals 
were given during training and 
then reinforced with oral and visual 
reminders. For these techniques to 
be effective and to have an impact 
on the ethical conduct of employees, 
  Table 2.   Ethical Issues Faced by Study Companies   
Company Size Name of Company Issues Faced
Small Interleukin Genetics This company was dealing with the question of how to develop and sell their product, given that there are no concrete 
best practices for trials and sale of nutrigenomic products. This company also faced a decision on whether and how 
best to merge with their now parent company, Alticor. 
Small Sciona This company was dealing with the question of how to develop and sell their product, given that there are no concrete 
best practices for trials and sale of nutrigenomic products. Ethical issues in nutrigenomics include privacy with respect 
to the collection, use, and storage of genetic information, and also the method of delivery of results to the consumer 
(whether through a professional or direct-to-user).
Small TGN Biotech This company produces transgenic animals and were faced primarily with ethical issues surrounding animal welfare.
Small Pipeline Biotech This company’s ethical issues have to do with animal welfare.
Medium PharmaSNPs This company dealt with issues in the area of pharmacogenomics, which included how to properly collect, store, 
and use human genetic information. Issues of consent, privacy, and discrimination resulting from genotyping were 
discussed.
Medium Maxim Pharmaceuticals This company addressed business ethics issues such as good governance, and also mentioned that they faced tough 
ethical challenges within clinical trials on how to handle compassionate use requests for drugs.
Medium Diversa This company addressed how to ethically collect biologic genetic material from other countries so they were not 
“stealing” genetic information. The company addressed the question of how to work to enhance biodiversity in their 
endeavors and also how to create partnerships with public organizations.
Medium Affymetrix This company addressed issues associated with personalized medicine and pharmacogenomics, such as maintaining 
privacy of the genetic information of donors and attaining proper consent. Interviewees explained ethical concerns 
about whether they should be commercializing genomics at all. Other issues included what would happen if their 
chips were used by contractors/partners for either illegal or “immoral” ends.
Large Genzyme This company faced ethical issues in clinical trials (consent of minors, including very sick and desperate patients in 
these trials). This company was also facing how to handle numerous requests for compassionate-use donations and 
how to get drugs to very sick patients in countries without national health coverage and to patients in the US who 
cannot afford their treatments. The company also faced the issue of how to price ultra-orphan drugs that are very 
expensive to produce.
Large Millennium Pharmaceuticals This company faced issues associated with pharmacogenomics, with respect to consent and use of personal genetic 
information. The company also mentioned challenges of maintaining core ethical values as the company grows.
Large Monsanto This company’s previously narrow stakeholder model excluded the public’s concerns about the production and sale 
of genetically modiﬁ  ed seeds. These concerns related to the impact of Genetically Modiﬁ  ed Organisms on the natural 
environment and on human health.
Large Novo Nordisk This company mentioned that they previously had a narrow stakeholder model that excluded the general public and 
some consumer concerns, and was more focused on the ﬁ  nancial bottom line. The company also faced ethical issues 
surrounding animal welfare and issues associated with working in or with developing countries: for instance, what 
types of programs to help implement, and how to give control and voice to the recipient countries. They also address 
human rights issues, particularly with their partners in other countries.
Large Merck Interviewees from this company said they faced issues on how to balance their spending on corporate donation 
programs with pressures from investors. They also explained ethical issues with publications of trial results: how much 
to publish and what to publish. Ethical issues associated with working in and with developing countries (what are the 
best programs to support that will beneﬁ  t all parties, public and private?) were also a focus of the case study.
  The ethical issues described above are examples of the issues interviewees said their companies were facing at the time of the interviews.
  DOI:  10.1371/journal.pmed.0030129.t002 
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our interviewees explained that they 
need to be continually and consistently 
reinforced by management.
    Approach Four: External Ethics 
Engagement
      Ethics mechanisms with partners and 
suppliers.   Of the 13 companies, seven, 
spanning all sizes, have extended 
their ethics approach to their business 
partners—to share the beneﬁ  ts created 
by these companies and/or to try 
to ensure that their partners also 
follow high ethical standards. The 
primary bioindustry ethics mechanism 
used by Diversa, for example, is the 
beneﬁ  t-sharing partnerships they 
have developed with countries that 
are involved with the collection of 
biological samples. Instead of secretly 
taking genetic material from these 
countries, referred to as “biopiracy,” 
Diversa forms partnerships—with, for 
example, a national park—to collect 
and process samples. In return, the 
company provides its partner with 
some up-front funding and training, 
along with a royalty percentage on 
any discoveries that originate from the 
samples.
    Novo Nordisk has extended 
its Triple Bottom Line approach 
beyond the company to include its 
suppliers, who must ﬁ  ll out a social/
environmental survey to assess whether 
they are following the same social and 
environmental norms to which Novo 
Nordisk ascribes. If a supplier is found 
to be violating some of these norms, 
Novo Nordisk will work with them to 
improve their standards. 
      Transparent engagement 
mechanisms with stakeholders.   
Companies of all sizes in our study 
(seven of the 13) are engaging with 
external stakeholders on ethical 
issues, although this seemed to 
become more of a necessity as ﬁ  rms 
became larger and higher-proﬁ  le. 
These stakeholders include local 
communities, nongovernmental 
organizations, governments, interest 
groups, and consumers. One example 
is Novo Nordisk’s invitations to animal 
welfare activist groups to tour its labs 
and to discuss potential solutions 
to their differences. Explained one 
Novo Nordisk VP: “It was successful 
because of the openness and because 
we weren’t seeking consensus. What 
we were seeking was to understand 
each other and to look for areas 
of commonality… However, some 
companies think that the dialogue is 
sufﬁ  cient. But it’s not. It requires action 
and responsiveness. There has to be a 
tangible outcome.”
    Another example of listening 
to stakeholders and acting on 
stakeholder concerns includes TGN 
Biotech’s efforts to engage citizens of 
a community in which the company 
planned to build a pig farm. They held 
an information night to educate the 
community about their science and to 
answer their questions. Interviewees 
explained that if the community 
had decided that it did not want the 
company to build the genetically 
modiﬁ  ed pig farm in their community, 
the company was committed to ﬁ  nding 
another location.
      Transparency of science.   Some of the 
fear in society about new science and 
technology stems from a perception 
that companies develop their science 
and technology secretively and do 
not share negative results. The Vioxx 
incident with Merck, which occurred 
after our study, demonstrates the 
importance of transparency. According 
to our ﬁ  ndings, this is one area where 
companies are presently struggling 
to ﬁ  nd a balance between protecting 
important patent and research 
information and the need to be 
transparent in a manner that will meet 
public satisfaction. One mechanism 
to address this issue was highlighted 
by the Director of Clinical Reporting 
at Novo Nordisk, who reported that 
the company tries its best to publish 
academic papers on every study to the 
greatest extent possible—regardless of 
whether the study shows negative or 
positive results.
      Inﬂ  uencing industry standards 
and regulations.   A majority of the 
companies we studied were engaged 
in discussions with regulators and 
industry bodies to encourage the 
ethical adoption of new science and 
technology. Some of the smaller 
ﬁ  rms were working to devise the best 
method of regulation for an emerging 
science as demonstrated by Interleukin 
and Sciona (nutrigenomics) and 
TGN Biotech (transgenesis to make 
therapeutic proteins). Others were 
working with industry groups to 
encourage the use of high ethical 
standards in areas of genetic 
information privacy (as done by 
Affymetrix), animal testing (Pipeline 
Biotech), and human rights standards 
(Novo Nordisk). 
      Strategic philanthropy.   Philanthropic 
and drug donation programs are 
a way for companies to give back 
to, and engage with, society. The 
latter strategy tends to be limited to 
the larger ﬁ  rms that have reached 
proﬁ  tability, while smaller ﬁ  rms 
donate employee time and expertise 
to address societal needs. Merck has 
created a nonproﬁ  t foundation that 
has invested hundreds of millions of 
dollars in public–private partnerships 
to help build infrastructure and deliver 
needed drugs in Africa and South 
America to address HIV/AIDS, and 
for other health crises, such as river 
blindness. Another example is Novo 
Nordisk’s World Diabetes Foundation, 
which supports partnerships and 
initiatives around the world that help 
build health infrastructure and health-
care capacity in these countries. Novo 
Nordisk works with local organizations 
and governments to learn what is 
needed from the developing country’s 
perspective.
  Box 2. BioIndustry Ethics 
Mechanisms 
  Ethical  leadership
  •  Founder/CEO/management  ethical 
leadership
  •  An  ethics  department
  External  expertise
  •  External  ethics  consultant
  •  Ethics  advisory  boards
  Internal  ethics  mechanisms 
    •  Hiring practices focused on ethics
  •  Employee  performance  evaluations
    •  Ethics education and forums for ethics 
discussion
  •  Ethical  reinforcement  techniques
  External  ethics  engagement
    •  Ethics mechanisms with partners and 
suppliers
  •  Transparent  engagement  mechanisms 
with stakeholders
  •  Transparency  of  science
  •  Inﬂ  uencing industry standards and 
regulations
  •  Strategic  philanthropy
    Ethics evaluation and reporting 
mechanisms 
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    Approach Five: Ethics Evaluation 
and Reporting Mechanisms
    From our interviews, we found that a 
few of these companies have methods 
for evaluating their approach to 
ethics and for reporting their ethics 
commitments to stakeholders. Our 
study originally intended to collect 
evaluations of each ethics mechanism 
in order to assess the effectiveness of 
different approaches. Unfortunately, 
we found that too few of the companies 
we interviewed are evaluating their 
approach to ethics for us to obtain 
concrete results. However, the 
following is a description of a few of the 
evaluation and reporting mechanisms 
that are starting to be used by some of 
the larger companies in our study. 
    Merck now requires that every 
philanthropic initiative they invest 
in to be subject to an evaluation 
process in order to assess whether it 
truly produced the beneﬁ  t sought, 
both for the recipient and for the 
company. Novo Nordisk has internal 
ethics auditors who rotate through 
departments and perform ethics 
assessments on how well employees 
are living up to their ethical mandates. 
These ethics auditors evaluate 
the department and help devise 
improvement strategies on an as-
needed basis. Both Monsanto and 
Novo Nordisk have a mechanism in 
place that reports to the public on 
their initiatives. Monsanto’s Pledge 
Progress Reports and Novo Nordisk’s 
Sustainability Reports are meant to 
transparently describe the companies’ 
stances on issues and their efforts to 
live up to their ethical promises. 
    Our ﬁ  ndings in the area of ethics 
evaluation demonstrate a need for 
future development and research. For 
bioscience companies who are more 
familiar with tangible and quantitative 
outcomes (with respect to share price, 
market share, and scientiﬁ  c data and 
results), it is challenging to devise 
a method to evaluate something as 
intangible as ethics. Employee surveys, 
public opinion polls, share price, and 
product acceptance levels were some of 
the measurement approaches suggested 
during our interviews. Although many 
of the companies studied are not 
evaluating the effectiveness of their 
ethics mechanisms, it was very clear 
that companies feel that evaluating 
their ethics approaches in order to 
learn from their successes and failures 
is a vital component of any bioindustry 
ethics initiative.
    Limitations of Our Approach
    The objective of this paper is to 
highlight speciﬁ  c mechanisms used 
by companies to address their ethical 
issues. However, we recognize that 
the views of senior management of 
bioscience companies are not the only 
relevant perspectives on these issues. We 
feel that one important next step would 
be to engage the opinions of other 
key players, such as nongovernmental 
organizations, governments, academics, 
and the general public.
    Another limitation of a study such 
as this is the risk of social desirability 
bias. This occurs when the research 
participant expresses a viewpoint that 
he or she thinks the interviewer wants 
to hear rather than what he or she 
truly believes. Although management 
opinions were given in this research 
study, the mechanisms described 
in this article are not opinions but 
rather a description of mechanisms 
being used by the companies—and, 
thus, they are less subject to bias. At 
each company, the descriptions of 
the mechanisms were given by more 
than one interviewee, and in most 
cases, we had documents supporting 
the fact that these mechanisms do 
occur as described. We recognize 
these limitations, but feel that because 
the people we interviewed are closest 
to the phenomenon, they represent 
a legitimate viewpoint and a highly 
logical entry point for empirical 
research into why and how bioscience 
companies address ethical issues.
  Conclusion
    Our study uncovered ﬁ  ve interrelated 
approaches, each with several 
mechanisms to address bioindustry 
ethics. Based on our ﬁ  ndings, a 
company of any size can start with 
strong ethical leadership and seek 
external ethics expertise early 
on. Internal ethics mechanisms 
and external ethics engagement 
mechanisms are other approaches 
that a bioscience company of any size 
can implement. As demonstrated by 
the larger companies in our study, 
companies can also develop ethics 
evaluation and reporting mechanisms 
that aim to keep the company on 
track and encourage management to 
monitor the outcomes of their ethical 
decision making. The mechanisms 
reported in this article demonstrate 
ideas for ways in which management 
in the bioscience industry can begin 
to address the complex ethical issues 
facing their companies.   
  Box 3. Why Are Bioscience 
Companies Addressing 
BioIndustry Ethics?
    •  Do the “right thing”
  •  Risk  mitigation
  •  Public  reputation
    •  Attract and keep the “right” employees
    •  Guidance in uncharted waters
  •  Promote  good  science 
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